Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005017230 | SCV005640631 | likely pathogenic | Polycystic kidney disease, adult type | 2024-05-24 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004726212 | SCV005338832 | uncertain significance | PKD1-related disorder | 2024-08-17 | no assertion criteria provided | clinical testing | The PKD1 c.664G>C variant is predicted to result in the amino acid substitution p.Ala222Pro. This variant has been reported in individuals with autosomal dominant polycystic kidney disease (ADPKD) (Liang et al. 2019. PubMed ID: 31730820; Kim et al. 2021. PubMed ID: 32816041). This variant has not been reported in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |